Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!
What is the Projected CAGR for the Vasoactive Intestinal Peptide Tumor Market Size from 2025 to 2034?
The market size of the vasoactive intestinal peptide tumor has seen significant growth in the last few years. It is predicted to increase from $1.51 billion in 2024 to $1.61 billion in 2025, displaying a compound annual growth rate (CAGR) of 6.5%. The growth during the historical period is due to the rising occurrence of VIP tumors, heightened attention to research and development activities, growing consciousness about health care, development in healthcare infrastructure, and partnerships between biotech companies and scientific research bodies.
The market size of vasoactive intestinal peptide tumors is predicted to witness substantial growth in the forthcoming years. The market is projected to escalate to $2.05 billion by 2029, with a compound annual growth rate (CAGR) of 6.3%. The growth anticipated in the forecast period can be ascribed to factors such as the escalating demand for chemotherapy, swift approval of drugs, surging demand for oral medications, heightened awareness about the disease, and the rising occurrence of tumors. Key trends within the forecast period encompass developments in targeted therapy, advancements in diagnostic methods, progression in treatment options, tailored medicine, targeted therapies, and innovative product introductions.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23561&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Vasoactive Intestinal Peptide Tumor Market?
The vasoactive intestinal peptide tumor market is expected to experience growth due to the upswing in targeted therapy. Focusing on specific molecules or pathways involved in cancer and disease progression, targeted therapies selectively attack abnormal cells, causing minimum damage to normal ones. Precision medicine, which hones in on specific genetic mutations and minimizes side effects, propels this upward trend. It aims to reduce VIP levels by blocking significant pathways that influence tumor growth and hormone release, thus alleviating symptoms like severe diarrhea and slow disease progression. For instance, the American Society of Gene and Cell Therapy (ASGCT) reports that 76 gene therapy trials were started in the second quarter of 2024, a 25% increase from the previous quarter – further evidencing the driving role targeted therapy plays in the vasoactive intestinal peptide tumor market’s growth. Additionally, the vasoactive intestinal peptide tumor market is likely to expand due to the rising incidence of neuroendocrine tumors combined with an increase in awareness, which leads to earlier detection. Characterized by traits of both nerve cells and hormone-producing cells, neuroendocrine tumors (NETs) are slowly progressing cancers that are becoming more prevalent due to advancements in diagnostic technology. This improvement allows for more precise detection of these previously under diagnosed tumors. Vasoactive intestinal peptide (VIP) tumors are a rare subtype of NETs, identified by excessive VIP secretion, causing severe diarrhea and electrolyte imbalance. As Cancer Australia, a government agency based in Australia, reported in September 2024, by age 85, the lifetime risk of being diagnosed with neuroendocrine tumors is estimated at 1 in 55, or approximately 1.8%. This risk is higher for males, at 1 in 52 (1.9 %), compared to females, at 1 in 58 (1.7 %). This data underscores the growing occurrence of neuroendocrine tumors, which is promoting the expansion of the vasoactive intestinal peptide tumor market.
Which Key Market Segments Comprise the Vasoactive Intestinal Peptide Tumor Market and Drive Its Revenue Growth?
The vasoactive intestinal peptide tumor market covered in this report is segmented –
1) By Treatment: Surgical Intervention, Radiotherapy, Chemotherapy, Targeted Therapy
2) By Diagnosis: Imaging Techniques, Biopsy, Endoscopic Ultrasound
3) By Therapeutic Approach: Palliative Care, Curative Treatment, Adjuvant Treatment
4) By End-User: Hospitals, Cancer Specialty Clinics, Diagnostic Laboratories
Subsegments:
1) By Surgical Intervention: Tumor Resection, Debulking Surgery, Minimally Invasive Surgery
2) By Radiotherapy: External Beam Radiation Therapy (EBRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy
3) By Chemotherapy: Cytotoxic Chemotherapy, Combination Chemotherapy, Adjuvant And Neoadjuvant Chemotherapy
4) By Targeted Therapy: Somatostatin Analog Therapy, Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23561&type=smp
Which Areas Are Leading Regions in the Vasoactive Intestinal Peptide Tumor Market Expansion Across the Globe?
North America was the largest region in the vasoactive intestinal peptide tumor market in 2024. The regions covered in the vasoactive intestinal peptide tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Vasoactive Intestinal Peptide Tumor Market?
Leading corporations in the vasoactive intestinal peptide tumor market are concentrating on the advancement of products such as long-acting injectable suspensions to boost the efficiency of treatment, enhance patient adherence, and provide persistent relief from symptoms. These types of medication slowly release their active components over an extended duration, reducing the frequency of dosage. For example, in October 2024, Teva Pharmaceutical Industries Ltd., an American pharmaceutical enterprise, introduced the first and sole generic variant of Sandostatin LAR Depot (octreotide acetate for injectable suspension) within the United States. This drug serves as a long-lasting maintenance therapy for acromegaly patients who responded poorly to surgery or radiotherapy. Moreover, it treats severe diarrhea and flushing symptoms associated with metastatic carcinoid tumors and VIP-secreting tumors. This launch emphasizes Teva’s proficiency in intricate generics and aids in achieving its target of sustaining a robust status in the generic pharmaceuticals market.
View the full report here:
How Is the Vasoactive Intestinal Peptide Tumor Market Conceptually Defined?
A vasoactive intestinal peptide (VIP) tumor, also known as VIPoma, is a rare neuroendocrine tumor that typically arises in the pancreas. It secretes excessive amounts of VIP, leading to severe watery diarrhea, dehydration, and electrolyte imbalances. Elevated VIP levels in the blood confirm the diagnosis, and treatment may involve surgery, medications, or targeted therapies.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23561
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model